In Vivo Model Development for Influenza

Ace Therapeutics offers a comprehensive in vivo animal model development service tailored for influenza research and therapeutic testing. Our platform leverages a broad spectrum of validated animal models, encompassing multiple species and genetic backgrounds, to accurately recapitulate the complexity of influenza infection and facilitate the development of effective antiviral strategies.

Animal models are indispensable tools in influenza research, enabling the study of viral pathogenesis, host immune responses, and the preclinical evaluation of vaccines and therapeutics. At Ace Therapeutics, we utilize a diverse portfolio of species—including mice (Mus musculus), ferrets (Mustela putorius), guinea pigs (Cavia porcellus), golden hamsters (Mesocricetus auratus), ducks (Anas platyrhynchos), pigs (Sus scrofa), rabbits (Oryctolagus cuniculus), rats (Rattus norvegicus), and tree shrews (Tupaia belangeri chinensis)—across a range of strains and genetic modifications. Notably, mouse models such as Balb/c, C57BL/6, and various knockout or immunodeficient lines provide valuable insights into immune mechanisms and genetic susceptibility. Ferrets, pigs, and tree shrews closely mimic human influenza in terms of viral tropism and clinical manifestations, making them essential for translational studies. This diversity allows us to select or customize the most scientifically relevant model for each research objective, ensuring data with high translational value to human disease.

Wild-Type Infection Models

These models involve the direct infection of immunocompetent animals (e.g., Balb/c, C57BL/6, CD-1 mice; ferrets; guinea pigs; pigs; ducks) with influenza virus strains. Animals are typically inoculated intranasally with a defined viral dose, and disease progression is monitored through clinical scoring, virological assays, and immunological analyses. Key advantages include the ability to study natural host-pathogen interactions and the evaluation of candidate therapeutics and vaccines in a physiologically relevant context. Primary research applications encompass antiviral drug screening, vaccine efficacy testing, and pathogenesis studies.

Genetically Engineered Models

Genetically engineered models utilize animals with targeted gene knockouts, knock-ins, or transgenic modifications (e.g., Lepr-/-, Fcer1g-/-, Fcgr2b-/-, Ifnar1-/-, SCID mice) to dissect the role of specific host factors in influenza susceptibility, immune response, or disease progression. Methodologies include the use of CRISPR/Cas9 or traditional gene-targeting to generate mice with altered immune pathways or metabolic profiles. Advantages of these models include precise mechanistic insights and the ability to model human genetic diseases or immunodeficiencies. They are instrumental for studying host-pathogen interactions, immune signaling, and evaluating interventions in genetically defined backgrounds.

Immunosuppressed and Disease-Compromised Models

This model type involves animals with induced or inherent immunosuppression (e.g., SCID mice, immunosuppressed ferrets, Balb/c mice with chemical or genetic immunodeficiency) or comorbidities (e.g., db/db diabetic mice). Methodologies may include genetic engineering, chemical induction, or pharmacological immunosuppression. These models are particularly advantageous for assessing influenza pathogenesis and therapeutic efficacy in vulnerable populations, such as the immunocompromised or those with chronic disease. Applications include testing antiviral strategies for high-risk patient groups and studying severe or atypical influenza outcomes.

Ace Therapeutics delivers an end-to-end solution for in vivo influenza model development and testing. Our service includes model selection and customization, ethical animal procurement and husbandry, precise viral or bacterial challenge, and comprehensive monitoring. Key efficacy endpoints include survival analysis, body weight and clinical scoring, viral load quantification (qPCR, TCID50, plaque assay), histopathology, cytokine and immune profiling, serological assays, and lung function assessment. Our analytical capabilities extend to next-generation sequencing, flow cytometry, and multiplex immunoassays, ensuring deep mechanistic insight. Rigorous quality control is maintained through standardized protocols, validated reagents, and GLP-compliant procedures, guaranteeing reproducibility and data integrity.

Partnering with Ace Therapeutics ensures access to a scientifically robust, customizable, and regulatory-aligned in vivo influenza research platform. Our multidisciplinary team provides expert guidance from model selection through data interpretation, accelerating your therapeutic discovery and development pipeline. Contact us today to discuss your project needs and leverage our expertise for impactful influenza research.